키오라 파마슈티컬스(KPRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.76 (+3.37%), 시가총액 $0.01B, 52주 최저~최고 $1.80 ~ $3.90.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-10
키오라 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
키오라 파마슈티컬스의 현재 주가는 $2.76 (+3.37%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
키오라 파마슈티컬스의 시가총액은 약 $0.01B입니다.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product